Skip to content
Screener

Alnylam Pharmaceuticals ALNY Q2 2026 earnings

Reported July 30, 2026 · Before market open

Revenue$1.3BMiss by $31.2M
Adjusted EPS$1.84Beat by $0.21
Revenue estimate$1.3B
EPS estimate$1.63
“During the second quarter, we also continued to advance our high-value pipeline with the initiation of two Phase 2 studies, ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer's disease, while progressing multiple additional programs toward important clinical readouts later this year. Together, these achievements demonstrate our continued progress against our Alnylam 2030 strategy and our commitment to creating long-term value through scientific innovation and patient impact.”
Yvonne Greenstreet

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$1.4B
EPS estimate$2.19

Financials

Q2 2026

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$31.98B-46.3%
Enterprise value$30.53B-48.0%
P/E43.6×—
P/S6.7×-17.5×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%—
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Segments

By product

See full
AMVUTTRA$1.0B+106%
GIVLAARI$89.8M+11.0%
OXLUMO$52.1M+11.2%
ONPATTRO$18.5M-64.9%

FAQ

When did Alnylam Pharmaceuticals report Q2 2026 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q2 2026 earnings on July 30, 2026 before market open.
What were Alnylam Pharmaceuticals's Q2 2026 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $1.3B and adjusted eps of $1.84 for Q2 2026.
Did Alnylam Pharmaceuticals beat estimates in Q2 2026?
Revenue missed the consensus estimate of $1.3B by $31.2M. EPS beat the consensus estimate of $1.63 by $0.21.
How did Alnylam Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 66.9% from $773.7M a year earlier.
Where can I find Alnylam Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001178670-26-000060) and the 10-Q periodic report (0001178670-26-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.